MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- NEULAND LABS - ADCOCK INGRAM (S. Africa)
NEULAND LABS vs ADCOCK INGRAM (S. Africa) - Comparison Results
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 NEULAND LABS  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| NEULAND LABS Mar-20 |
ADCOCK INGRAM Jun-14 |
NEULAND LABS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 754 | 383 | - | |
| Low | Rs | 247 | 276 | - | |
| Sales per share (Unadj.) | Rs | 594.5 | 113.9 | - | |
| Earnings per share (Unadj.) | Rs | 12.6 | -28.7 | - | |
| Cash flow per share (Unadj.) | Rs | 37.0 | -23.8 | - | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 553.4 | 89.4 | - | |
| Shares outstanding (eoy) | m | 12.83 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.8 | 2.9 | 29.1% | |
| Avg P/E ratio | x | 39.6 | -11.5 | -345.0% | |
| P/CF ratio (eoy) | x | 13.5 | -13.9 | -97.6% | |
| Price / Book Value ratio | x | 0.9 | 3.7 | 24.5% | |
| Dividend payout | % | 15.8 | 0 | - | |
| Avg Mkt Cap | Rs m | 6,421 | 55,608 | 11.5% | |
| No. of employees | `000 | 1.3 | 4.3 | 29.9% | |
| Total wages/salary | Rs m | 1,236 | 3,490 | 35.4% | |
| Avg. sales/employee | Rs Th | 5,949.4 | 4,476.9 | 132.9% | |
| Avg. wages/employee | Rs Th | 963.8 | 813.0 | 118.5% | |
| Avg. net profit/employee | Rs Th | 126.4 | -1,128.1 | -11.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 7,627 | 19,219 | 39.7% | |
| Other income | Rs m | 39 | 135 | 28.9% | |
| Total revenues | Rs m | 7,666 | 19,354 | 39.6% | |
| Gross profit | Rs m | 1,019 | -3,331 | -30.6% | |
| Depreciation | Rs m | 313 | 829 | 37.7% | |
| Interest | Rs m | 216 | 521 | 41.4% | |
| Profit before tax | Rs m | 529 | -4,546 | -11.6% | |
| Minority Interest | Rs m | 0 | -13 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 367 | 284 | 129.2% | |
| Profit after tax | Rs m | 162 | -4,843 | -3.3% | |
| Gross profit margin | % | 13.4 | -17.3 | -77.1% | |
| Effective tax rate | % | 69.4 | -6.2 | -1,110.2% | |
| Net profit margin | % | 2.1 | -25.2 | -8.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 5,152 | 14,076 | 36.6% | |
| Current liabilities | Rs m | 3,576 | 7,920 | 45.2% | |
| Net working cap to sales | % | 20.7 | 32.0 | 64.5% | |
| Current ratio | x | 1.4 | 1.8 | 81.1% | |
| Inventory Days | Days | 105 | 111 | 94.7% | |
| Debtors Days | Days | 91 | 124 | 73.3% | |
| Net fixed assets | Rs m | 3,969 | 8,205 | 48.4% | |
| Share capital | Rs m | 129 | 89 | 144.6% | |
| Net worth | Rs m | 7,100 | 15,085 | 47.1% | |
| Long term debt | Rs m | 774 | 5,301 | 14.6% | |
| Total assets | Rs m | 12,310 | 28,497 | 43.2% | |
| Interest coverage | x | 3.5 | -7.7 | -44.7% | |
| Debt to equity ratio | x | 0.1 | 0.4 | 31.0% | |
| Sales to assets ratio | x | 0.6 | 0.7 | 91.9% | |
| Return on assets | % | 3.1 | -15.2 | -20.2% | |
| Return on equity | % | 2.3 | -32.1 | -7.1% | |
| Return on capital | % | 9.5 | -19.8 | -47.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 573 | 1,640 | 35.0% | |
| From Investments | Rs m | -487 | -504 | 96.6% | |
| From Financial Activity | Rs m | -55 | 4,811 | -1.1% | |
| Net Cashflow | Rs m | 33 | 5,948 | 0.5% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.28 Rs / ZAR
Compare NEULAND LABS With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare NEULAND LABS With: PROCTER & GAMBLE HEALTH AUROBINDO PHARMA WOCKHARDT FRESENIUS KABI ONCO. SANOFI INDIA
Today's Market
March Quarter Results, Aditya Birla Sun Life AMC IPO and Buzzing Stocks Today(Pre-Open)
On Tuesday, Indian share markets witnessed volatile trading activity and ended lower.
Related Views On News
NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)
Feb 3, 2021 | Updated on Feb 3, 2021For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.
NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)
Sep 2, 2020 | Updated on Sep 2, 2020Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
More
